Summary
Amgen Inc. (AMGN) filed an 8-K on May 22, 2018, reporting the results of its Annual Meeting of Stockholders held on May 21, 2018. The primary focus of the report is the voting outcomes on key corporate governance and executive matters. All director nominees were overwhelmingly elected, and shareholders approved the company's executive compensation on an advisory basis. Additionally, the selection of Ernst & Young LLP as the independent registered public accountants for the fiscal year ending December 31, 2018, was ratified by a substantial margin. Notably, a stockholder proposal requesting an annual report on the integration of drug pricing risks into executive incentive compensation was not approved by the majority of shareholders. This filing provides transparency on shareholder engagement and the outcomes of critical votes that influence the company's governance and operational oversight.
Key Highlights
- 1All 13 director nominees were overwhelmingly elected to serve one-year terms.
- 2Shareholders approved the executive compensation plan on an advisory ('say-on-pay') basis with significant support.
- 3Ernst & Young LLP was ratified as Amgen's independent registered public accountants for the fiscal year 2018.
- 4A stockholder proposal concerning the integration of drug pricing risks into executive compensation was not approved.
- 5The Annual Meeting of Stockholders took place on May 21, 2018, with final voting results detailed in the filing.